PDS290 clinical trials

Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?

This study looks at whether a medicine called semaglutide (often known as Ozempic) can help people with schizophrenia on certain antipsychotic medicines. Researchers want to see if it can prevent or slow down problems with blood sugar, like pre-diabetes or diabetes, in these patients.